Qualification Statement

Qualification of the Diary for Irritable Bowel Syndrome Symptoms–Constipation: A Patient-Reported Outcome Instrument for Measurement of Overall Irritable Bowel Syndrome–Constipation Symptom Severity

Date: December 18, 2020

DDT Type: Clinical Outcome Assessment (COA)

DDT Tracking Number: DDTCOA-000005

Referenced COA: Diary for Irritable Bowel Syndrome Symptoms – Constipation (DIBSS-C)

Type of COA: Patient-Reported Outcome (PRO) Instrument

The Center for Drug Evaluation and Research (CDER) has determined that the measures of abdominal pain, abdominal symptoms (abdominal pain, discomfort, bloating), complete spontaneous bowel movement (CSBM) frequency, and straining with bowel movements (BMs) based on the DIBSS-C instrument have demonstrated adequate evidence of content validity and cross-sectional measurement properties (i.e., internal consistency reliability, test-retest reliability, convergent validity, and known-groups validity) for the context of use described below.

Section I: COA Concept of Interest

The DIBSS-C measures the following aspects of symptom experience associated with irritable bowel syndrome with constipation (IBS-C):¹

The BM-Related Symptoms Domain assesses the following symptoms as individual items:

- Stool frequency²
- Incomplete BMs²
- Straining with BMs
- Stool consistency

The Abdominal Symptoms Domain assesses the following symptoms as a composite score:

- Abdominal pain
- Abdominal discomfort

¹ There is no single overall composite score for the DIBSS-C.
² The “stool frequency” and “incomplete BM” items are used to calculate complete spontaneous bowel movements (CSBMs).
• Abdominal bloating

**Section II: Context of Use**

This qualification statement supports the DIBSS-C weekly abdominal pain intensity score, weekly abdominal symptoms domain (abdominal pain, discomfort, bloating) score, weekly complete spontaneous BM frequency, and weekly straining with BMs score as measures of their respective concepts to derive efficacy endpoints in drug development clinical trials for products intended to treat irritable bowel syndrome with constipation (IBS-C) in adults. Further evaluation is warranted regarding the instrument’s longitudinal measurement properties (i.e., ability to detect change) and the interpretation of clinically meaningful within-patient change in score. It is recommended that this information be obtained in drug development programs in consultation with the FDA.

Sponsors seeking to use the DIBSS-C in confirmatory studies to assess study endpoint(s) should refer to the final FDA IBS Guidance\(^3\) and should discuss the approach with the appropriate CDER review division.

The recommended target patient population is described as follows:

- Adults aged 18 years and older
- Patients with a diagnosis of IBS-C as defined by Rome Criteria and the final FDA IBS Guidance, including:
  - Patients who report a weekly average of worst daily (in past 24 hours) abdominal pain score of \(\geq 3.0\) on a 0 to 10-point scale
  - Patients who report fewer than three CSBMs per week

**Section III: Interpretation of Change**

Information to support thresholds for clinically meaningful within-patient changes in the DIBSS-C item scores and abdominal symptom subscale score is needed. We recommend that for regulatory submissions, thresholds for clinically meaningful within-patient changes on these scores be proposed and confirmed within the clinical trial context, preferably prior to use in confirmatory studies.

**Section IV: Contact Information for Access to the Qualified COA**

Patient-Reported Outcome Consortium
Critical Path Institute
1730 E. River Road
Tucson, AZ 85718

For more information, please send email to: procadmin@c-path.org; Subject: DIBSS-C

---

\(^3\) FDA Guidance for Industry: Irritable Bowel Syndrome (final) — Clinical Evaluation of Drugs for Treatment (2012). Available at: [https://www.fda.gov/media/78622/download](https://www.fda.gov/media/78622/download). We update guidances periodically. To make sure you have the most recent version of a guidance, check the FDA guidance web page at [https://www.fda.gov/RegulatoryInformation/Guidances/default.htm](https://www.fda.gov/RegulatoryInformation/Guidances/default.htm).
Inquiry

**Instructions for Use in a Regulatory Submission:** Please reference DDT COA #000005 in your regulatory application.